// App-Quantinova.ai

Filters

Biomarkers











Conference Name











Country

























Company

Search valid company name..

Conference Year













Drug











Disease











Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























486 Abstracts

A phase 2 study of galunisertib, a novel transforming growth factor-beta (TGF-) receptor I kinase inhibitor, in patients with advanced hepatocellular carcinoma (HCC) and low serum alpha fetoprotein (AFP).

Sandrine J. Faivre - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

LY2157299

Mature results of the GETUG 13 phase III trial in poor-prognosis germ-cell tumors

Karim Fizazi - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Germ cell tumor

Oxaliplatin

SIOPEL 6: A multi-centre open label randomized phase III trial of the efficacy of Sodium Thiosulphate in reducing ototoxicity in patients receiving cisplatin chemotherapy for standard risk hepatoblastoma.

Penelope Rachel Brock - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Hepatoblastoma

sodium thiosulfate

Vincristine/irinotecan upfront window treatment of high-risk hepatoblastoma: A report from the Children's Oncology Group (COG) AHEP0731 study committee.

Howard M. Katzenstein - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Hepatoblastoma

Alfa-fetoprotein

MRX34, a liposomal miR-34 mimic and potential first-in-class microRNA therapeutic: activity in animal models of liver cancer.

Chris Daige - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Liver cancer

Sorafenib

Validation of clinical scoring systems ART and ABCR after transarterial chemoembolization of hepatocellular carcinoma.

Roman Kloeckner - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

N/A

Clinicopathologic and prognostic features of hepatocellular carcinoma (HCC) due to metabolic syndrome (MS) compared to chronic liver disease (CLD) and cryptogenic causes (CC).

Matthew L Chase - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Liver cancer

N/A

Overall survival of liver transplantation for hepatocellular carcinoma in the elderly.

Tanmay Sahai - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

N/A

Primary peritoneal hepatoid adenocarcinoma: Response to platin based chemotherapy.

Basak Oyan - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

Alkaline phosphatase

Chemotherapy efficacy and prognosis of patients with mediastinal seminoma. Single institution experience.

Mikhail Fedyanin - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Seminoma

Cyclophosphamide

A randomized, double-blind, placebo-controlled phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2).

Andrew X. Zhu - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2016

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Liver cancer

Alfa-fetoprotein

PHOCUS: A phase 3 randomized, open-label study comparing the oncolytic immunotherapy pexaavec followed by sorafenib (SOR) vs SOR in patients with advanced hepatocellular carcinoma (HCC) without prior systemic therapy.

Ghassan K. Abou-Alfa - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

Sorafenib

REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib.

Andrew X. Zhu - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Alfa-fetoprotein

Unresectable hepatocellular carcinoma treated with lenvatinib or sorafenib: A disease modeling study.

Gabriel Tremblay - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Alfa-fetoprotein

Detection of early recurrence in HCC patients after TACE treatment with plasma cfDNA.

Xiao Du - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

A pilot study to assess the accuracy of intuition in analyzing post chemotherapy (chemo) residual retroperitoneal (RP) masses in patients (pts) with non seminomatous germ cell tumor (NSCGCT).

Clint Cary - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Second-line tivantinib (ARQ 197) vs placebo in patients (Pts) with MET-high hepatocellular carcinoma (HCC): Results of the METIV-HCC phase III trial.

Lorenza Rimassa - American Society of Clinical Oncology (ASCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Tivantinib

FDG PET scan (PET) positive residual lesions after chemotherapy (chemo) for metastatic seminoma: Results of an International Global Germ Cell Cancer Group (G3) registry.

Richard Cathomas - American Society of Clinical Oncology (ASCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Efficacy of regorafenib (REG) in patients with hepatocellular carcinoma (HCC) in the phase III RESORCE trial according to alpha-fetoprotein (AFP) and c-Met levels as predictors of poor prognosis.

Michael Teufel - American Society of Clinical Oncology (ASCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Alfa-fetoprotein

Biopsy practices for the diagnosis of hepatocellular carcinoma (HCC).

Alison L Raybould - American Society of Clinical Oncology (ASCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved